Ï㽶ÊÓƵ

Charles J. Parker
( out of 44 reviews )

Charles J. Parker, MD, AB

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626

Sugar House Health Center

Salt Lake City
801-581-2000

Veterans Administration Medical Center

Salt Lake City

  • Charles J. Parker, M. D., is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, at the Ï㽶ÊÓƵ of Utah and the Huntsman Cancer Institute, Salt Lake City, UT. As a Hematologist, his clinical interests include paroxysmal nocturnal hemoglobinuria (PNH), hemochromatosis and porphyria.



    Dr. Parker received his MD from The Ï㽶ÊÓƵ of North Carolina, Chapel Hill. He received training in medicine and hematology from the North Carolina Memorial Hospital, Chapel Hill and Duke Ï㽶ÊÓƵ, respectively. In the past, Dr. Parker served as President of the International Paroxysmal Nocturnal Hemoglobinuria Interest Group and Editor-in-Chief of The Hematologist.


    For questions regarding Dr. Parker's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Hematology)
    Educational Commission for Foreign Medical Graduates
    Licentiate of the Medical Council of Canada
    Royal College of Physicians and Surgeons of Canada
    Royal College of Surgeons of Canada

    Patient Rating

    4.6 /5
    ( out of 44 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 17, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Parker was easy to understand. He explained his thoughts in a manner I could understand.

    April 11, 2024
    SUGAR HOUSE HEALTH CENTER

    Absolutely love Dr. Parker and his PA! His concern for me and my health was absolutely amazing! The staff as a whole in his clinic are extremely friendly and helpful!

    April 07, 2024
    SUGAR HOUSE HEALTH CENTER

    He was. Amazing and the nicest bed side manner

    March 26, 2024
    SUGAR HOUSE HEALTH CENTER

    Very understanding and clear with information.

    March 16, 2024
    SUGAR HOUSE HEALTH CENTER

    He is a great doctor

    March 15, 2024
    SUGAR HOUSE HEALTH CENTER

    His experience as a hematologist was very apparent. Where other doctors had said, ¿We just don't know what's wrong,¿ Dr. Parker ordered tests to see exactly what's going on with me personally. A kind, gentle doctor.

    March 14, 2024
    SUGAR HOUSE HEALTH CENTER

    Very informative and knowledgeable

    January 18, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Parker was very thorough in his review of my test results. I appreciate him wanting to wait and review my MRI with the radiologist when Dr. Parker noted contradictory or inconsistent interpretations. I also appreciate his description of what he was doing, keeping me informed.

    December 23, 2023
    SUGAR HOUSE HEALTH CENTER

    Dr. Parker is incredibly knowledge and helpful. His personal review and interpretation of my blood smear helped him to provide an informed decision about my condition. He is personable and calm and conveys a sense of certainty.

    See More Patient Comments

  • Charles J. Parker, M. D., is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, at the Ï㽶ÊÓƵ of Utah and the Huntsman Cancer Institute, Salt Lake City, UT. As a Hematologist, his clinical interests include paroxysmal nocturnal hemoglobinuria (PNH), hemochromatosis and porphyria.



    Dr. Parker received his MD from The Ï㽶ÊÓƵ of North Carolina, Chapel Hill. He received training in medicine and hematology from the North Carolina Memorial Hospital, Chapel Hill and Duke Ï㽶ÊÓƵ, respectively. In the past, Dr. Parker served as President of the International Paroxysmal Nocturnal Hemoglobinuria Interest Group and Editor-in-Chief of The Hematologist.


    For questions regarding Dr. Parker's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at or (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Hematology)
    Educational Commission for Foreign Medical Graduates
    Licentiate of the Medical Council of Canada
    Royal College of Physicians and Surgeons of Canada
    Royal College of Surgeons of Canada

    Education history

    Fellowship Hematology/Oncology - Duke Ï㽶ÊÓƵ Medical Center Fellow
    Internal Medicine - North Carolina Memorial Hospital Resident
    Internship North Carolina Memorial Hospital Intern
    Medicine - Ï㽶ÊÓƵ of North Carolina M.D.
    Undergraduate English - Ï㽶ÊÓƵ of North Carolina A.B.

    Selected Publications

    Journal Article

    1. Balwani M, Bonkovsky HL, Levy C, Anderson KE, Bissell DM, Parker C, Takahashi F, Desnick RJ, Belongie K, Endeavor Investigators (2023). Dersimelagon in Erythropoietic Protoporphyrias. N Engl J Med, 388(15), 1376-1385. ()
    2. Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker C (2022). Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. Br J Haematol, 198(6), e78-e81. ()
    3. Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peir P, Montgomery Bissell D, Stein PE, Balwani M, Anderson DKE, Parker C, Kuter DJ, Monroy S, Oh J, Ritchie B, Ko JJ, Hua Z, Sweetser MT, Sardh E, ENVISION Investigators (2021). Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int, 42(1), 161-172. ()
    4. Farrell CP, Nicolas G, Desnick RJ, Parker CJ, Lamoril J, Gouya L, Karim Z, Tchernitchko D, Chen B, Puy H, Phillips JD (2021). ABCB6 Polymorphisms are not Overly Represented in Patients with Porphyria. Blood Adv. ()
    5. Abou-Ismail MY, Prchal JT, Deininger MW, Parker CJ, Lim MY (2021). Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms. Blood Coagul Fibrinolysis, 32(8), 578-583. ()
    6. Thiagarajan P, Parker CJ, Prchal JT (2021). How Do Red Blood Cells Die? Front Physiol, 12, 655393. ()
    7. Parker CJ, Desnick RJ, Bissel MD, Bloomer JR, Singal A, Gouya L, Puy H, Anderson KE, Balwani M, Phillips JD (2019). Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. Mol Genet Metab, 128(3), 309-313. ()
    8. Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ (2015). Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med, 373(1), 48-59. ()
    9. Singal AK, Parker C, Bowden C, Thapar M, Liu L, McGuire BM (2014). Liver transplantation in the management of porphyria. Hepatology, 60(3), 1082-9. ()
    10. Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns BR, Prchal JT (2012). Methylation of AR locus does not always reflect X chromosome inactivation state. Blood, 119(13), e100-9. ()
    11. Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ (2010). In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Exp Hematol, 39(1), 14-25. ()
    12. Parker CJ, Brodsky RA, Levine JE (2009). Treatment versus transplant for challenging hematologic disorders. Biol Blood Marrow Transplant, 15(1 Suppl), 72-8. ()
    13. Parker CJ, Janatova J, Weis JH (2000). Preface. Immunopharmacology, 49(1-2), 99-100. ()
    14. Bohnsack JF, Widjaja K, Ghazizadeh S, Rubens CE, Hillyard DR, Parker CJ, Albertine KH, Hill HR (1997). A role for C5 and C5a-ase in the acute neutrophil response to group B streptococcal infections. J Infect Dis, 175(4), 847-55. ()
    15. Liu L, Murray DK, Dameron CT, Parker CJ, Rodgers GM (1997). Biochemical characterization of procoagulant albumin. Thromb Res, 85(5), 399-411. ()
    16. Gubler DB, Ahlstrom CR, Liu L, Zhou JF, Parker CJ, Rodgers GM (1995). Procoagulant albumin increases vascular endothelial cell prostacyclin secretion. Thromb Haemost, 74(6), 1573-7. ()
    17. Grosset A, Liu L, Parker CJ, Rodgers GM (1994). Bioassay of procoagulant albumin in human plasma. Thromb Res, 75(5), 551-8. ()
    18. Tomita A, Radike EL, Parker CJ (1993). Isolation of erythrocyte membrane inhibitor of reactive lysis type II. Identification as glycophorin A. J Immunol, 151(6), 3308-23. ()
    19. Gubler DB, Wilson BD, Parker CJ, Rodgers GM (1993). Regulation of endothelial cell protein C activation and fibrinolysis by procoagulant albumin. Thromb Res, 70(6), 459-69. ()
    20. Ezzell JL, Parker CJ (1992). Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity. Scand J Immunol, 36(1), 79-87. ()
    21. Bohnsack JF, Zhou XN, Gustin JN, Rubens CE, Parker CJ, Hill HR (1992). Bacterial evasion of the antibody response: human IgG antibodies neutralize soluble but not bacteria-associated group B streptococcal C5a-ase. J Infect Dis, 165(2), 315-21. ()
    22. Holguin MH, Martin CB, Bernshaw NJ, Parker CJ (1992). Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor. J Immunol, 148(2), 498-502. ()
    23. Bohnsack JF, Zhou XN, Williams PA, Cleary PP, Parker CJ, Hill HR (1991). Purification of the proteinase from group B streptococci that inactivates human C5a. Biochim Biophys Acta, 1079(2), 222-8. ()
    24. Janatova J, Cheung AK, Parker CJ (1991). Biomedical polymers differ in their capacity to activate complement. Complement Inflamm, 8(2), 61-9. ()
    25. Lassiter HA, Speranza MJ, Hall RT, Meade V, Christensen RD, Parker CJ (1990). Complement C3 deposition onto bacteria by neonatal serum is not enhanced after the infusion of intravenous immunoglobulin. J Perinatol, 10(1), 27-31. ()
    26. Parker CJ, Bernshaw NJ, Wilcox LA (1990). Analysis of the binding of human C3b to glycoproteins on rabbit and sheep erythrocytes. Complement Inflamm, 7(1), 1-17. ()
    27. Cheung AK, Parker CJ, Wilcox L (1989). Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure. Clin Exp Immunol, 78(2), 299-306. ()
    28. Lassiter HA, Christensen RD, Parker CJ (1989). Immunologic regulation of E. coli K1 by serum from neonatal rats is enhanced following intraperitoneal administration of human IgG. J Infect Dis, 159(3), 518-25. ()
    29. Parker CJ, Stone OL, Bernshaw NJ (1989). Characterization of the enhanced susceptibility of paroxysmal nocturnal hemoglobinuria erythrocytes to complement-mediated hemolysis initiated by cobra venom factor. J Immunol, 142(1), 208-16. ()
    30. Hill HR, Bohnsack JF, Morris EZ, Augustine NH, Parker CJ, Cleary PP, Wu JT (1988). Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol, 141(10), 3551-6. ()
    31. Whatley RE, Lewis MS, Zimmerman GA, McIntyre TM, Parker CJ, Stevens DL, Prescott SM (1988). The regulation of synthesis of platelet-activating factor by endothelial cells. Chest, 93(3 Suppl), 110S-111S. ()

    Review

    1. Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Barton JC, Parker CJ (1993). HFE-Related Hemochromatosis. [Review]. Gene Reviews. ()
    2. Parker CJ (2012). Paroxysmal nocturnal hemoglobinuria. [Review]. Curr Opin Hematol, 19(3), 141-8. ()
    3. Parker CJ (2011). Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. [Review]. Hematology Am Soc Hematol Educ Program, 2011, 21-9. ()
    4. Parker, CJ (2011). Complement and hematology. [Review]. 8(1), 5.

    Book Chapter

    1. Parker CJ (2017). Complement and PNH. In Kanakura Y, Kinoshita T, Nishimura J (Eds.), Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bedside (pp. 67-98). Tokyo: Springer Japan KK.
    2. Parker CJ (2015). Paroxysmal Nocturnal Hemoglobinuria. In Kaushansky K, Lichtman M, Kipps T, Prchal J, Seligsohn U (Eds.), Williams Hematology (9th Edition). Boston: McGraw-Hill.
    3. Parker CJ (2015). Complement for the Clinician. In Brodsky R (Ed.), Complement-mediated Hemolytic Anemias, An Issue of Hematology/Oncology Clinics of North America. Philadelphia: Elsevier.
    4. Parker CJ, Ware RE (2014). Paroxysmal Nocturnal Hemoglobinuria. In Orkin S, Nathan G, Ginsburg D, Look AT, Fisher D, Lux S (Eds.), Nathan and Oski's Hematology and Oncology of Infancy and Childhood (8th Edition). Philadelphia: Elsevier.
    5. Parker, CJ and Ware, RE (2013). Paroxysmal nocturnal hemoglobinuria. In Greer J, Arber D, Glader B, List A, Means R, Paraskevas F, Rodgers G, Foerster J (Eds.), Wintrobe's Clinical Hematology (13th Ed, pp. 785-808). Philadelphia: Lippincott Williams & Wilkins.

    Letter

    1. Trunk AD, Shewan SK, Lee CJ, Parker CJ, Couriel DR (2022). Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination. [Letter to the editor]. Bone Marrow Transplant, 57(3), 502-503. ()

  • Clinical Trials